The coronavirus vaccines are still making headlines these days. As you probably know by now, vaccines have been surrounded by controversies ever since they started rolling out throughout the world.
Speaking about vaccines, the other day, we revealed that Israeli officials are warning that the Pfizer vaccine is “significantly less” effective against the Delta variant of the coronavirus – just in case you don’t know, the strain first seen in India that now accounts for 31 percent of cases in the US.
“We do not know exactly to what degree the vaccine helps, but it is significantly less,” said Israeli Prime Minister Naftali Bennett.
It’s been revealed that the shot is still keeping people from getting seriously ill in Israel over 60 percent of the population has received a jab.
Just 1.6 percent have become critically ill, compared with 4 percent in the pre-vax wave of cases.- the NY Post notes.
Pfizer and Moderna vaccines
News Medical Net notes that US experts have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response.
It’s important to note that this is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The team of experts is from the University of California and they found that immunization with either Pfizer-BioNTech’s BNT162b2 or Moderna’s mRNA-1273 vaccine-induced enrichment of spike-specific B cells.
The online publication mentioned above notes that infection and vaccination offer two different pathways towards immunization.
“Our study highlights a coordinated adaptive immune response where early CD4 T cell responses facilitate the development of the B cell response and substantial expansion of effector CD8 T cells, together capable of contributing to future recall responses,” concludes the team.
We suggest that you check out the complete article in order to learn more details about the issue.